ClinicalTrials.Veeva

Menu

Comparison of Imaging Quality Between Spectral Photon Counting Computed Tomography (SPCCT) and Dual Energy Computed Tomography (DECT) (SPEQUA)

Civil Hospices of Lyon logo

Civil Hospices of Lyon

Status

Enrolling

Conditions

Coronary Artery Disease
Joint Diseases
Kidney Stone
Macroadenoma
Inner Ear Disease
Diabetic Foot Ulcer
Interstitial Lung Disease
Brain Stroke
Diabetes
Hyperaldosteronism
Parenchymatous; Pneumonia
Intracranial Arteriovenous Malformations
Adrenal Incidentaloma

Treatments

Device: Spectral Photon Counting Computed Tomography (SPCCT)
Device: DECT (Dual Energy CT)

Study type

Interventional

Funder types

Other

Identifiers

NCT04328181
69HCL19_0486
ID-RCB (Other Identifier)

Details and patient eligibility

About

This pilot study wants to determine to which extent SPCCT allows obtaining images with improved quality and diagnostic confidence when compared to standard Dual Energy CT (DECT), both with and without contrast agent injection.

Depending on the anatomical structures/organs to be visualized during CT examinations, different scanning protocols are performed with quite variable ionizing radiation doses. Therefore, in order to obtain the most extensive and representative results of the improvement in image quality between SPCCT and DECT that will be performed CT imaging on several body regions and structures, including diabetic foot, diabetic calcium coronary scoring, adrenal glands, coronary arteries, lung parenchyma, kidney stones, inner ear, brain and joints, earl/temporal bone, colorectal carcinosis.

Enrollment

339 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients presenting following one of following medical conditions:

    1. Asymptomatic type 1 or 2 diabetes as regard to cardiovascular risks
    2. Diabetic foot ulcer
    3. Adrenal glands lesions: Adrenal incidentaloma or hyperaldosteronism or macroadenoma
    4. Urinary stone(s)
    5. Known Coronary artery disease: Stent imaging or control of calcified plaques
    6. Diffuse Interstitial Lung Diseases: Idiopathic Pulmonary Fibrosis, Hypersensitivity Pneumonitis, Ground Glass Opacification, Chronic Thromboembolic Pulmonary Hypertension
    7. Conductive hearing loss
    8. Brain stroke (late or post thrombectomy)
    9. Intracranial arteriovenous malformation treated with coils or Onyx
    10. Joints diseases in haemophilia
    11. Ear/temporal bone
    12. Colorectal carcinosis
    13. Dissection aortique de type A opérée ou de type B non opérée, hématome intramural
  • Patient has accepted to participate to the study and has signed the written consent;

  • Pre-menopausal women only: Negative urinary pregnancy test on the day of imaging before the administration of study drug;

  • Patient is affiliated to the French social security

Exclusion criteria

  • Contraindication to the use of iodine containing contrast media (including subjects with suspicion for/or known to have NSF) (if injection);
  • History of severe allergic or anaphylactic reaction to any allergen including drugs and contrast agents (as judged by the investigator, taking into account the intensity of the event);
  • History of delayed major or delayed cutaneous reaction to Iomeron injection
  • Estimated Glomerular Filtration Rate (eGFR) value < 30 mL/min/1.73 m2 derived from a serum creatinine result within 1 month before the imaging for examinations with contrast agent.
  • Any subject on hemodialysis or peritoneal dialysis;
  • Suspected clinical instability or unpredictability of the clinical course during the study period (e.g. due to previous surgery);
  • Pregnant or nursing (including pumping for storage and feeding);
  • Patient under guardianship, curatorship or safeguard of justice.

Trial design

Primary purpose

Diagnostic

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

339 participants in 1 patient group

SPCCT and standard DECT
Experimental group
Description:
Comparative intra-patients (each patient will have both types of scanner imaging done), clinical superiority study, evaluating the imaging performances (e.g. image quality and radiation dose) of SPCCT and standard DECT for several body regions/anatomical structures.
Treatment:
Device: Spectral Photon Counting Computed Tomography (SPCCT)
Device: DECT (Dual Energy CT)

Trial contacts and locations

1

Loading...

Central trial contact

Adeline MANSUY; Philippe DOUEK, Pr

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems